Incyte analyst coverage

Author: pvkp

August undefined, 2024

WebApr 4, 2024 · Incyte had a net margin of 10.03% and a return on equity of 11.45%. The company had revenue of $926.70 million during the quarter, compared to analyst estimates of $880.25 million. During the same period last year, the business earned ($0.07) EPS. Incyte's quarterly revenue was up 7.4% compared to the same quarter last year. WebDec 29, 2024 · Incyte (NASDAQ:INCY) provides the potential for very high returns, based on analysts' EPS estimates and a high P/E multiple. There are also significant downside risks if EPS growth estimates are ...

INCY Stock Forecast, Price & News (Incyte) - MarketBeat

WebDec 29, 2024 · Incyte ( NASDAQ: INCY) provides the potential for very high returns, based on analysts' EPS estimates and a high P/E multiple. There are also significant downside risks if EPS growth estimates... list of black congressmen

Incyte Stock (NASDAQ:INCY), Analyst Ratings, Price Targets ... - Benzinga

WebApr 11, 2024 · What are analysts forecasts for Incyte stock? The 39 analysts offering price forecasts for Incyte have a median target of 84.23, with a high estimate of 113.00 and a low estimate of 56.00. WebMar 25, 2024 · StockNews.com assumed coverage on Incyte in a report on Thursday, March 16th. They set a "strong-buy" rating on the stock. ... The company had revenue of $926.70 million for the quarter, compared to analyst estimates of $880.25 million. Incyte had a return on equity of 11.45% and a net margin of 10.03%. The business's revenue was up 7.4% on a … WebMar 11, 2024 · Incyte's ruxolitinib, a type of non-steroidal anti-inflammatory medication called a JAK inhibitor, already makes up a major chunk of earnings, representing $2.22 billion of the company's $2.46 ... list of black congress women

Incyte Corporation (INCY) Stock Price, News & Historical Data

INCY Stock News INCYTE Stock Price Today - Insider

WebMar 28, 2024 · According to 13 analyst offering 12-month price targets in the last 3 months, Incyte has an average price target of $94.23 with a high of $113.00 and a low of $60.00. WebIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. list of black colleges in usaWebApr 9, 2024 · Incyte Co. (NASDAQ:INCY) Receives $86.23 Average PT from Analysts Posted by ABMN Staff on Apr 9th, 2024 Shares of Incyte Co. ( NASDAQ:INCY – Get Rating) have been given an average rating of “Hold” by the eighteen brokerages that are presently covering the company, Marketbeat.com reports. list of black crystals and stones

"WebAnalyst Recommendations The current consensus among 21 polled investment analysts is to Hold stock in Incyte Corp. This rating has held steady since April, when it was downgraded from a Buy rating. " - Incyte analyst coverage

Incyte analyst coverage

Incyte Corporation Just Reported A Surprise Loss: Here

WebApr 10, 2024 · Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact' Mar. 24, 2024 at 11:28 a.m. ET on Benzinga.com Incyte (INCY) Gets CRL for Jakafi Extended ... WebApr 12, 2024 · Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and COMPASS Pathways (CMPS) - Compass Pathways (NASDAQ:CMPS), Incyte (NASDAQ:INCY) - Benzinga Companies in...

Did you know?

WebBased on 13 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $87.46 with a high forecast of $113.00 and a low forecast of $61.00 . The average price target represents a … WebApr 12, 2024 · For the last few months, analysts have been revising downwards their earnings forecast. Over the past twelve months, analysts' consensus has been significantly revised downwards. Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

WebJan 24, 2024 · The FDA has set a March 23 target date under the Prescription Drug User Fee Act (PDUFA) to decide on Incyte’s new drug application (NDA) for a once-daily extended-release version of ruxolitinib... WebApr 12, 2024 · -- Incyte has an average outperform rating and price target range of $61 to $118, according to analysts polled by Capital IQ. Price: 74.54, Change: +0.37, Percent Change: +0.50 ... April 12, 2024 ... Rankings Coverage. Screeners Stock Screener Home. Investment Themes. Ageing Population. Sin stocks. The SPAC ...

WebAug 30, 2024 · Incyte Corporation (INCY) Stock Price, News & Historical Data - TheStreet Join TheStreet® SMARTS today for only $1! [ Healthcare ] [ Biotechnology ] [ INCY ] Incyte Corporation INCY... WebApr 13, 2024 · Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. About the company. INCY fundamental analysis. Snowflake Score. …

WebFeb 9, 2024 · These 4 analysts have an average price target of $74.25 versus the current price of Incyte at $68.65, implying upside. Below is a summary of how these 4 analysts rated Incyte over the past 3 months.

WebMar 22, 2024 · An Incyte cancer drug that was turned down by the FDA two years ago was granted an unexpected approval Wednesday in a different type of cancer, a regulatory decision that now pits the new product... images of scott laudatiWebIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages,... list of black directorsWebIncyte Corporation (INCY) Analyst Ratings, Estimates & Forecasts - Yahoo Finance S&P Futures 3,973.50 -4.50(-0.11%) Dow Futures 32,280.00 -39.00(-0.12%) Nasdaq Futures 12,836.50 -17.50(-0.14%)... images of scottish menWebJan 18, 2024 · Within the last quarter, Incyte (NASDAQ:INCY) has observed the following analyst ratings: list of black congressmanWebApr 10, 2024 · Based on 10 analyst s offering ratings for Incyte Corp. Buy Strong Buy 2 analysts 20% Buy 2 analysts 20% Hold 5 analysts 50% Sell 1 analysts 10% Strong Sell 0 analysts 0% Be the first to know when Wall Street analysts revise their INCY stock forecasts and price targets. Get Free INCY Updates INCY stock forecasts by analyst All Analysts … images of scottish highland cattleWebApr 10, 2024 · Analyst coverage for Incyte stock is good. Key information 29.0% Earnings growth rate 28.0% EPS growth rate Recent future growth updates Aug 03 Aug 03 First quarter 2024 earnings: EPS and revenues miss analyst expectations May 03 Show all updates Earnings and Revenue Growth Forecasts Show more Analyst Future Growth … images of scottish terriersWebNov 2, 2024 · In Q3 2024 it had sales of $38 million, more than doubling its Q2 sales. Considerable time was devoted to discussing its sales ramp during the Q3 Incyte Analyst Conference. The number of potential ... images of scottish highlands